Printer Friendly

Actavis files Abbreviated New Drug Application seeking approval for Ambrisentan Tablets.

M2 EQUITYBITES-April 6, 2015-Actavis files Abbreviated New Drug Application seeking approval for Ambrisentan Tablets

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Actavis plc (NYSE: ACT), an Ireland-based global pharmaceutical company, announced on Friday that it has filed an Abbreviated New Drug Application seeking approval with the US Food and Drug Administration to market Ambrisentan Tablets, five mg and 10 mg.

The company's Abbreviated New Drug Application product is a generic version of Gilead Sciences, Inc.'s Letairis(R), which is a treatment for pulmonary arterial hypertension.

The company believes it is likely to be a 'first applicant' to file an Abbreviated New Drug Application for the generic version of Letairis, and should its Abbreviated New Drug Application be approved it is expected to be entitled to 180 days of generic market exclusivity.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 6, 2015
Words:144
Previous Article:AOL debuts 'Assist by AOL' in Minneapolis and St. Paul.
Next Article:Prescription Hope launches new national programme.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters